Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | GLA | P06280 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | BIRC5 | O15392 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18135122 | 0.80 | KDM4E (0.48) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL15665313 | 0.72 | KMT2A (0.57) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL22866493 | 0.67 | KDM4E (0.38) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL16740891 | 0.67 | KDM4E (0.43) | KDM4EDHODH | |
| SCHEMBL29559825 | 0.67 | KDM4E (0.38) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL13280215 | 0.66 | KDM4E (0.49) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL562812 | 0.66 | KDM4E (1.00) | KDM4EGAAALDH1A1GLAHPGD | |
| SCHEMBL23885743 | 0.66 | KIF11 (0.55) | MAPTKIF11 | |
| SCHEMBL30054111 | 0.66 | PLA2G1B (0.54) | KDM4EKIF11KMT2AMEN1 | |
| SCHEMBL23885645 | 0.66 | PLA2G1B (0.54) | KDM4EKIF11KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738630-B2 | Inhibitors of lysine methyl transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015077193-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297806-A1 | INHIBITORS OF LYSINE METHYL TRANSFERASE | EZH2, DOT1L, EHMT1 | KDM4E 24/4885GAA 2686/4885ALDH1A1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.